Drug Profile
Research programme: anti-cancer monoclonal antibodies - Xenova/Aurelium
Alternative Names: Anti-cancer monoclonal antibodies research programme - KS Biomedix/Aurelium BioPharma; KSB 108Latest Information Update: 28 Jul 2004
Price :
$50
*
At a glance
- Originator Aurelium BioPharma; Xenova Group
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 27 Jul 2004 Discontinued - Preclinical for Haematological malignancies in Canada (unspecified route)
- 27 Jul 2004 Discontinued - Preclinical for Haematological malignancies in United Kingdom (unspecified route)
- 25 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group